Table 3.
Logistic regression to assess the risk associated with lanreotide use for incident gallstones
| OR (95% CI) | p value | |
|---|---|---|
| Univariate | ||
| Lanreotide use | 22.5 (2.96–171) | < 0.01 |
| Multivariate | ||
| Lanreotide use | 25.9 (3.37–199) | < 0.01 |
| Female sexa | 1.66 (0.59–4.66) | 0.33 |
| Age, years | 1.04 (0.97–1.12) | 0.28 |
| BMI, kg/m2a | 0.95 (0.83–1.09) | 0.46 |
| Baseline liver volume (ml) | 1.00 (1.00–1.00) | 0.16 |
| Baseline eGFR (ml/1.73m2/min) | 1.00 (0.96–1.05) | 0.90 |
Significant factors via multivariable analysis are highlighted in bold
OR odds ratio, CI confidence interval, BMI body mass index, eGFR estimated glomerular filtration rate, as calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
aInteraction terms for sex * lanreotide and BMI * lanreotide were not significant